Loading…

Utility of systemic voriconazole in equine keratomycosis based on pharmacokinetic‐pharmacodynamic analysis of tear fluid following oral administration

Objective To clarify the detailed pharmacokinetics (PK) of orally administered voriconazole in tear fluid (TF) of horses for evaluating the efficacy of voriconazole secreted into TF against equine keratomycosis. Animals studied Five healthy Thoroughbred horses. Procedures Voriconazole was administra...

Full description

Saved in:
Bibliographic Details
Published in:Veterinary ophthalmology 2020-07, Vol.23 (4), p.640-647
Main Authors: Tamura, Norihisa, Okano, Atsushi, Kuroda, Taisuke, Niwa, Hidekazu, Kusano, Kanichi, Matsuda, Yoshikazu, Fukuda, Kentaro, Mita, Hiroshi, Nagata, Shunichi
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4154-9e9dad5d5fe4c34c40a1341c6b50268a83a261da5cfb3ce973b8041a5b5708a63
cites cdi_FETCH-LOGICAL-c4154-9e9dad5d5fe4c34c40a1341c6b50268a83a261da5cfb3ce973b8041a5b5708a63
container_end_page 647
container_issue 4
container_start_page 640
container_title Veterinary ophthalmology
container_volume 23
creator Tamura, Norihisa
Okano, Atsushi
Kuroda, Taisuke
Niwa, Hidekazu
Kusano, Kanichi
Matsuda, Yoshikazu
Fukuda, Kentaro
Mita, Hiroshi
Nagata, Shunichi
description Objective To clarify the detailed pharmacokinetics (PK) of orally administered voriconazole in tear fluid (TF) of horses for evaluating the efficacy of voriconazole secreted into TF against equine keratomycosis. Animals studied Five healthy Thoroughbred horses. Procedures Voriconazole was administrated through a nasogastric tube to each horse at a single dose of 4.0 mg/kg. TF and blood samples were collected before and periodically throughout the 24 hours after administration. Voriconazole concentrations in plasma and TF samples were analyzed using liquid chromatography‐electrospray tandem‐mass spectrometry. The predicted voriconazole concentration in both samples following multiple dosing every 24 hours was simulated by the superposition principle. Results The mean maximum voriconazole concentrations in plasma and TF were 3.3 μg/mL at 1.5 h and 1.9 μg/mL at 1.6 h, respectively. Mean half‐life in both samples were 16.4 and 25.2 h, respectively. The ratio of predicted AUC0–24 at steady state in TF (51.3 μg∙h/mL) to previously published minimum inhibitory concentration (MIC) of Aspergillus and Fusarium species was >100 and 25.7, respectively. Conclusions This study demonstrated the detailed single‐dose PK of voriconazole in TF after oral administration and simulated the predicted concentration curves in a multiple oral dosing. Based on the analyses of PK‐PD, the simulation results indicated that repeated oral administration of voriconazole at 4.0 mg/kg/d achieves the ratio of AUC to MIC associated with treatment efficacy against Aspergillus species. The detailed PK‐PD analyses against pathogenic fungi in TF can be used to provide evidence‐based medicine for equine keratomycosis.
doi_str_mv 10.1111/vop.12764
format article
fullrecord <record><control><sourceid>wiley_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7496923</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>VOP12764</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4154-9e9dad5d5fe4c34c40a1341c6b50268a83a261da5cfb3ce973b8041a5b5708a63</originalsourceid><addsrcrecordid>eNp1kU9PHCEYh0lTU63toV_AcO1hFYY_M3MxaYy2TUz0oL2Sd4BRlIEtzO5mPPUjePTz9ZOU7erGHsoFAs_7_Eh-CH2i5JCWdbSM80Na1ZK_QXuUSzYTVcXfbs9U7qL3Od8RQpgg9Tu0yyrWMFHJPfR0PTrvxgnHHucpj3ZwGi9jcjoGeIjeYhew_blwweJ7m2CMw6Rjdhl3kK3BMeD5LaQBdLwvzOj071-PLzdmCrD2QQA_rWdKyGgh4d4vnMF99D6uXLjBMYHHYAYXXB5LiIvhA9rpwWf78XnfR9dnp1cn32bnF1-_n3w5n2lOBZ-1tjVghBG95ZpxzQlQxqmWnSCVbKBhUElqQOi-Y9q2NesawimITtSkAcn20fHGO190gzXahvIBr-bJDZAmFcGpf1-Cu1U3calq3sq2YkXweSPQKeacbL-dpUSt61GlHvW3nsIevA7bki99FOBoA6yct9P_TerHxeVG-QfPKaH_</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Utility of systemic voriconazole in equine keratomycosis based on pharmacokinetic‐pharmacodynamic analysis of tear fluid following oral administration</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Tamura, Norihisa ; Okano, Atsushi ; Kuroda, Taisuke ; Niwa, Hidekazu ; Kusano, Kanichi ; Matsuda, Yoshikazu ; Fukuda, Kentaro ; Mita, Hiroshi ; Nagata, Shunichi</creator><creatorcontrib>Tamura, Norihisa ; Okano, Atsushi ; Kuroda, Taisuke ; Niwa, Hidekazu ; Kusano, Kanichi ; Matsuda, Yoshikazu ; Fukuda, Kentaro ; Mita, Hiroshi ; Nagata, Shunichi</creatorcontrib><description>Objective To clarify the detailed pharmacokinetics (PK) of orally administered voriconazole in tear fluid (TF) of horses for evaluating the efficacy of voriconazole secreted into TF against equine keratomycosis. Animals studied Five healthy Thoroughbred horses. Procedures Voriconazole was administrated through a nasogastric tube to each horse at a single dose of 4.0 mg/kg. TF and blood samples were collected before and periodically throughout the 24 hours after administration. Voriconazole concentrations in plasma and TF samples were analyzed using liquid chromatography‐electrospray tandem‐mass spectrometry. The predicted voriconazole concentration in both samples following multiple dosing every 24 hours was simulated by the superposition principle. Results The mean maximum voriconazole concentrations in plasma and TF were 3.3 μg/mL at 1.5 h and 1.9 μg/mL at 1.6 h, respectively. Mean half‐life in both samples were 16.4 and 25.2 h, respectively. The ratio of predicted AUC0–24 at steady state in TF (51.3 μg∙h/mL) to previously published minimum inhibitory concentration (MIC) of Aspergillus and Fusarium species was &gt;100 and 25.7, respectively. Conclusions This study demonstrated the detailed single‐dose PK of voriconazole in TF after oral administration and simulated the predicted concentration curves in a multiple oral dosing. Based on the analyses of PK‐PD, the simulation results indicated that repeated oral administration of voriconazole at 4.0 mg/kg/d achieves the ratio of AUC to MIC associated with treatment efficacy against Aspergillus species. The detailed PK‐PD analyses against pathogenic fungi in TF can be used to provide evidence‐based medicine for equine keratomycosis.</description><identifier>ISSN: 1463-5216</identifier><identifier>EISSN: 1463-5224</identifier><identifier>DOI: 10.1111/vop.12764</identifier><identifier>PMID: 32383526</identifier><language>eng</language><publisher>England: John Wiley and Sons Inc</publisher><subject>Administration, Oral ; Animals ; Antifungal Agents - administration &amp; dosage ; Antifungal Agents - pharmacokinetics ; Antifungal Agents - pharmacology ; Antifungal Agents - therapeutic use ; Area Under Curve ; Aspergillus ; Aspergillus - drug effects ; Eye Infections, Fungal - drug therapy ; Eye Infections, Fungal - veterinary ; Female ; horse ; Horse Diseases - blood ; Horse Diseases - drug therapy ; Horses - metabolism ; keratomycosis ; Male ; Microbial Sensitivity Tests ; Original ; pharmacodynamics ; pharmacokinetics ; tear fluid ; Tears - metabolism ; Voriconazole - administration &amp; dosage ; Voriconazole - pharmacokinetics ; Voriconazole - pharmacology ; Voriconazole - therapeutic use</subject><ispartof>Veterinary ophthalmology, 2020-07, Vol.23 (4), p.640-647</ispartof><rights>2020 The Authors. published by Wiley Periodicals LLC on behalf of American College of Veterinary Ophthalmologists</rights><rights>2020 The Authors. Veterinary Ophthalmology published by Wiley Periodicals LLC on behalf of American College of Veterinary Ophthalmologists.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4154-9e9dad5d5fe4c34c40a1341c6b50268a83a261da5cfb3ce973b8041a5b5708a63</citedby><cites>FETCH-LOGICAL-c4154-9e9dad5d5fe4c34c40a1341c6b50268a83a261da5cfb3ce973b8041a5b5708a63</cites><orcidid>0000-0002-9138-6839</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32383526$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tamura, Norihisa</creatorcontrib><creatorcontrib>Okano, Atsushi</creatorcontrib><creatorcontrib>Kuroda, Taisuke</creatorcontrib><creatorcontrib>Niwa, Hidekazu</creatorcontrib><creatorcontrib>Kusano, Kanichi</creatorcontrib><creatorcontrib>Matsuda, Yoshikazu</creatorcontrib><creatorcontrib>Fukuda, Kentaro</creatorcontrib><creatorcontrib>Mita, Hiroshi</creatorcontrib><creatorcontrib>Nagata, Shunichi</creatorcontrib><title>Utility of systemic voriconazole in equine keratomycosis based on pharmacokinetic‐pharmacodynamic analysis of tear fluid following oral administration</title><title>Veterinary ophthalmology</title><addtitle>Vet Ophthalmol</addtitle><description>Objective To clarify the detailed pharmacokinetics (PK) of orally administered voriconazole in tear fluid (TF) of horses for evaluating the efficacy of voriconazole secreted into TF against equine keratomycosis. Animals studied Five healthy Thoroughbred horses. Procedures Voriconazole was administrated through a nasogastric tube to each horse at a single dose of 4.0 mg/kg. TF and blood samples were collected before and periodically throughout the 24 hours after administration. Voriconazole concentrations in plasma and TF samples were analyzed using liquid chromatography‐electrospray tandem‐mass spectrometry. The predicted voriconazole concentration in both samples following multiple dosing every 24 hours was simulated by the superposition principle. Results The mean maximum voriconazole concentrations in plasma and TF were 3.3 μg/mL at 1.5 h and 1.9 μg/mL at 1.6 h, respectively. Mean half‐life in both samples were 16.4 and 25.2 h, respectively. The ratio of predicted AUC0–24 at steady state in TF (51.3 μg∙h/mL) to previously published minimum inhibitory concentration (MIC) of Aspergillus and Fusarium species was &gt;100 and 25.7, respectively. Conclusions This study demonstrated the detailed single‐dose PK of voriconazole in TF after oral administration and simulated the predicted concentration curves in a multiple oral dosing. Based on the analyses of PK‐PD, the simulation results indicated that repeated oral administration of voriconazole at 4.0 mg/kg/d achieves the ratio of AUC to MIC associated with treatment efficacy against Aspergillus species. The detailed PK‐PD analyses against pathogenic fungi in TF can be used to provide evidence‐based medicine for equine keratomycosis.</description><subject>Administration, Oral</subject><subject>Animals</subject><subject>Antifungal Agents - administration &amp; dosage</subject><subject>Antifungal Agents - pharmacokinetics</subject><subject>Antifungal Agents - pharmacology</subject><subject>Antifungal Agents - therapeutic use</subject><subject>Area Under Curve</subject><subject>Aspergillus</subject><subject>Aspergillus - drug effects</subject><subject>Eye Infections, Fungal - drug therapy</subject><subject>Eye Infections, Fungal - veterinary</subject><subject>Female</subject><subject>horse</subject><subject>Horse Diseases - blood</subject><subject>Horse Diseases - drug therapy</subject><subject>Horses - metabolism</subject><subject>keratomycosis</subject><subject>Male</subject><subject>Microbial Sensitivity Tests</subject><subject>Original</subject><subject>pharmacodynamics</subject><subject>pharmacokinetics</subject><subject>tear fluid</subject><subject>Tears - metabolism</subject><subject>Voriconazole - administration &amp; dosage</subject><subject>Voriconazole - pharmacokinetics</subject><subject>Voriconazole - pharmacology</subject><subject>Voriconazole - therapeutic use</subject><issn>1463-5216</issn><issn>1463-5224</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><recordid>eNp1kU9PHCEYh0lTU63toV_AcO1hFYY_M3MxaYy2TUz0oL2Sd4BRlIEtzO5mPPUjePTz9ZOU7erGHsoFAs_7_Eh-CH2i5JCWdbSM80Na1ZK_QXuUSzYTVcXfbs9U7qL3Od8RQpgg9Tu0yyrWMFHJPfR0PTrvxgnHHucpj3ZwGi9jcjoGeIjeYhew_blwweJ7m2CMw6Rjdhl3kK3BMeD5LaQBdLwvzOj071-PLzdmCrD2QQA_rWdKyGgh4d4vnMF99D6uXLjBMYHHYAYXXB5LiIvhA9rpwWf78XnfR9dnp1cn32bnF1-_n3w5n2lOBZ-1tjVghBG95ZpxzQlQxqmWnSCVbKBhUElqQOi-Y9q2NesawimITtSkAcn20fHGO190gzXahvIBr-bJDZAmFcGpf1-Cu1U3calq3sq2YkXweSPQKeacbL-dpUSt61GlHvW3nsIevA7bki99FOBoA6yct9P_TerHxeVG-QfPKaH_</recordid><startdate>202007</startdate><enddate>202007</enddate><creator>Tamura, Norihisa</creator><creator>Okano, Atsushi</creator><creator>Kuroda, Taisuke</creator><creator>Niwa, Hidekazu</creator><creator>Kusano, Kanichi</creator><creator>Matsuda, Yoshikazu</creator><creator>Fukuda, Kentaro</creator><creator>Mita, Hiroshi</creator><creator>Nagata, Shunichi</creator><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-9138-6839</orcidid></search><sort><creationdate>202007</creationdate><title>Utility of systemic voriconazole in equine keratomycosis based on pharmacokinetic‐pharmacodynamic analysis of tear fluid following oral administration</title><author>Tamura, Norihisa ; Okano, Atsushi ; Kuroda, Taisuke ; Niwa, Hidekazu ; Kusano, Kanichi ; Matsuda, Yoshikazu ; Fukuda, Kentaro ; Mita, Hiroshi ; Nagata, Shunichi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4154-9e9dad5d5fe4c34c40a1341c6b50268a83a261da5cfb3ce973b8041a5b5708a63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Administration, Oral</topic><topic>Animals</topic><topic>Antifungal Agents - administration &amp; dosage</topic><topic>Antifungal Agents - pharmacokinetics</topic><topic>Antifungal Agents - pharmacology</topic><topic>Antifungal Agents - therapeutic use</topic><topic>Area Under Curve</topic><topic>Aspergillus</topic><topic>Aspergillus - drug effects</topic><topic>Eye Infections, Fungal - drug therapy</topic><topic>Eye Infections, Fungal - veterinary</topic><topic>Female</topic><topic>horse</topic><topic>Horse Diseases - blood</topic><topic>Horse Diseases - drug therapy</topic><topic>Horses - metabolism</topic><topic>keratomycosis</topic><topic>Male</topic><topic>Microbial Sensitivity Tests</topic><topic>Original</topic><topic>pharmacodynamics</topic><topic>pharmacokinetics</topic><topic>tear fluid</topic><topic>Tears - metabolism</topic><topic>Voriconazole - administration &amp; dosage</topic><topic>Voriconazole - pharmacokinetics</topic><topic>Voriconazole - pharmacology</topic><topic>Voriconazole - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tamura, Norihisa</creatorcontrib><creatorcontrib>Okano, Atsushi</creatorcontrib><creatorcontrib>Kuroda, Taisuke</creatorcontrib><creatorcontrib>Niwa, Hidekazu</creatorcontrib><creatorcontrib>Kusano, Kanichi</creatorcontrib><creatorcontrib>Matsuda, Yoshikazu</creatorcontrib><creatorcontrib>Fukuda, Kentaro</creatorcontrib><creatorcontrib>Mita, Hiroshi</creatorcontrib><creatorcontrib>Nagata, Shunichi</creatorcontrib><collection>Open Access: Wiley-Blackwell Open Access Journals</collection><collection>Wiley Free Archive</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Veterinary ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tamura, Norihisa</au><au>Okano, Atsushi</au><au>Kuroda, Taisuke</au><au>Niwa, Hidekazu</au><au>Kusano, Kanichi</au><au>Matsuda, Yoshikazu</au><au>Fukuda, Kentaro</au><au>Mita, Hiroshi</au><au>Nagata, Shunichi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Utility of systemic voriconazole in equine keratomycosis based on pharmacokinetic‐pharmacodynamic analysis of tear fluid following oral administration</atitle><jtitle>Veterinary ophthalmology</jtitle><addtitle>Vet Ophthalmol</addtitle><date>2020-07</date><risdate>2020</risdate><volume>23</volume><issue>4</issue><spage>640</spage><epage>647</epage><pages>640-647</pages><issn>1463-5216</issn><eissn>1463-5224</eissn><abstract>Objective To clarify the detailed pharmacokinetics (PK) of orally administered voriconazole in tear fluid (TF) of horses for evaluating the efficacy of voriconazole secreted into TF against equine keratomycosis. Animals studied Five healthy Thoroughbred horses. Procedures Voriconazole was administrated through a nasogastric tube to each horse at a single dose of 4.0 mg/kg. TF and blood samples were collected before and periodically throughout the 24 hours after administration. Voriconazole concentrations in plasma and TF samples were analyzed using liquid chromatography‐electrospray tandem‐mass spectrometry. The predicted voriconazole concentration in both samples following multiple dosing every 24 hours was simulated by the superposition principle. Results The mean maximum voriconazole concentrations in plasma and TF were 3.3 μg/mL at 1.5 h and 1.9 μg/mL at 1.6 h, respectively. Mean half‐life in both samples were 16.4 and 25.2 h, respectively. The ratio of predicted AUC0–24 at steady state in TF (51.3 μg∙h/mL) to previously published minimum inhibitory concentration (MIC) of Aspergillus and Fusarium species was &gt;100 and 25.7, respectively. Conclusions This study demonstrated the detailed single‐dose PK of voriconazole in TF after oral administration and simulated the predicted concentration curves in a multiple oral dosing. Based on the analyses of PK‐PD, the simulation results indicated that repeated oral administration of voriconazole at 4.0 mg/kg/d achieves the ratio of AUC to MIC associated with treatment efficacy against Aspergillus species. The detailed PK‐PD analyses against pathogenic fungi in TF can be used to provide evidence‐based medicine for equine keratomycosis.</abstract><cop>England</cop><pub>John Wiley and Sons Inc</pub><pmid>32383526</pmid><doi>10.1111/vop.12764</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-9138-6839</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1463-5216
ispartof Veterinary ophthalmology, 2020-07, Vol.23 (4), p.640-647
issn 1463-5216
1463-5224
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7496923
source Wiley-Blackwell Read & Publish Collection
subjects Administration, Oral
Animals
Antifungal Agents - administration & dosage
Antifungal Agents - pharmacokinetics
Antifungal Agents - pharmacology
Antifungal Agents - therapeutic use
Area Under Curve
Aspergillus
Aspergillus - drug effects
Eye Infections, Fungal - drug therapy
Eye Infections, Fungal - veterinary
Female
horse
Horse Diseases - blood
Horse Diseases - drug therapy
Horses - metabolism
keratomycosis
Male
Microbial Sensitivity Tests
Original
pharmacodynamics
pharmacokinetics
tear fluid
Tears - metabolism
Voriconazole - administration & dosage
Voriconazole - pharmacokinetics
Voriconazole - pharmacology
Voriconazole - therapeutic use
title Utility of systemic voriconazole in equine keratomycosis based on pharmacokinetic‐pharmacodynamic analysis of tear fluid following oral administration
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T06%3A28%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Utility%20of%20systemic%20voriconazole%20in%20equine%20keratomycosis%20based%20on%20pharmacokinetic%E2%80%90pharmacodynamic%20analysis%20of%20tear%20fluid%20following%20oral%20administration&rft.jtitle=Veterinary%20ophthalmology&rft.au=Tamura,%20Norihisa&rft.date=2020-07&rft.volume=23&rft.issue=4&rft.spage=640&rft.epage=647&rft.pages=640-647&rft.issn=1463-5216&rft.eissn=1463-5224&rft_id=info:doi/10.1111/vop.12764&rft_dat=%3Cwiley_pubme%3EVOP12764%3C/wiley_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4154-9e9dad5d5fe4c34c40a1341c6b50268a83a261da5cfb3ce973b8041a5b5708a63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/32383526&rfr_iscdi=true